Contribution of allelic imbalance to colorectal cancer

Kimmo Palin, Esa Pitkänen, Mikko Turunen, Biswajyoti Sahu, Päivi Pihlajamaa, Teemu Kivioja, Eevi Kaasinen, Niko Välimäki, Ulrika A. Hänninen, Tatiana Cajuso, Mervi Aavikko, Sari Tuupanen, Outi Kilpivaara, Linda van den Berg, Johanna Kondelin, Tomas Tanskanen, Riku Katainen, Marta Grau, Heli Rauanheimo, Roosa‐Maria Plaketti, Aurora Taira, Päivi Sulo, Tuomo Hartonen, Kashyap Dave, Bernhard Schmierer, Sandeep K. Botla, Maria Sokolova, Anna Vähärautio, Kornelia Gladysz, Halit Ongen, Emmanouil T. Dermitzakis, Jesper B. Bramsen, Torben F. Ørntoft, Claus L. Andersen, Ari Ristimäki, Anna Lepistö, Laura Renkonen‐Sinisalo, Jukka‐Pekka Mecklin, Jussi Taipale, Lauri A. AaltonenNature Communications 2018 · DOI

TL;DR

This study provides a high-resolution map of allelic imbalance (AI) in colorectal cancer (CRC), identifying 38 key genes that are frequently gained or lost. They demonstrate that TP53 loss is a significant driver of AI and uncover a network of transcription factors that converge on MYC activation, offering new insights into CRC tumorigenesis and explaining why only a few genes are commonly mutated in cancers.

What Problem Does This Paper Address?

For decades, cancer research has heavily focused on point mutations as drivers of malignancy, leading to the identification of a relatively small set of frequently mutated genes. However, chromosomal gains and losses (allelic imbalances or AI) have been more challenging to interpret due to their broad, unspecific nature, often spanning thousands of genes. This lack of resolution has made it difficult to pinpoint the specific genes targeted by these large-scale genomic alterations. This paper aims to bridge this gap by providing a high-resolution analysis of AI in colorectal cancer, identifying specific gene targets and understanding their functional roles in cancer development.

Methods

The researchers employed a multi-pronged approach:

  • High-Resolution Allelic Imbalance (AI) Analysis: They analyzed AI in 1699 colorectal cancer (CRC) tumor/normal DNA pairs using SNP arrays. This technique allows for precise detection of gains and losses of genetic material at a high spatial resolution.
  • Whole-Genome Sequencing (WGS): A subset of 256 CRC samples underwent WGS to investigate the relationship between AI and somatic point mutations.
  • CRISPR-Cas9 Screens: To assess the functional impact of AI target genes on cell growth, they performed CRISPR-Cas9 knockout and activation screens in CRC cell lines. This allowed them to identify genes whose loss or overexpression affects cell proliferation.
  • Functional Genomics Assays: Techniques like ChIP-nexus/exo, siRNA, and RNA-seq were used to explore the regulatory relationships between AI target genes, particularly focusing on transcription factors.
  • TP53 Knockout Experiments: To investigate the role of TP53 loss in driving AI, they cultured normal human cells and TP53-null cell lines and analyzed their genomic stability.

Datasets

  • 1699 Colorectal Cancer (CRC) Tumor/Normal DNA Pairs: This large dataset was used for the primary AI analysis.
  • 256 Whole-Genome Sequenced (WGSed) CRC Samples: A subset of the 1699 samples was used for WGS to study the interplay between AI and somatic mutations.
  • 259 Additional Colorectal Tumors: These samples were used to validate the association between AI and gene expression.
  • CRC Cell Lines (GP5d, COLO320DM, CaCO2): These cell lines were used for CRISPR-Cas9 screens.
  • Normal Human RPE1 Cells and Clonal TP53-Null Lines: Used for experiments investigating the role of TP53 loss.

Key Insights and Ideas

  • AI as a Major Driver of CRC: The study strongly suggests that allelic imbalances play a more significant role in colorectal cancer development than previously appreciated, even outnumbering somatic point mutations in some cancer genes.
  • TP53 Loss as a Sufficient Driver of AI: The research provides compelling evidence that the loss of the TP53 tumor suppressor gene is sufficient to induce widespread genomic instability and allelic imbalances in cells.
  • A Network of Transcription Factors Converging on MYC: The study identifies a coordinated network of transcription factors whose AI is associated with colorectal tumorigenesis, and importantly, this network converges on the activation of the MYC oncogene.
  • Explaining the "Missing Heritability" of Cancer Genes: The findings offer a plausible explanation for why only a limited number of genes are commonly affected by point mutations in cancers. Instead of relying on multiple specific point mutations, cancer cells can achieve similar outcomes through large-scale AI events that broadly affect gene expression.
  • Isochromosome i(8q) and MYC Amplification: The study highlights the frequent formation of isochromosome i(8q) in CRC, which leads to the gain of the MYC oncogene and loss of the 8p arm, underscoring the importance of MYC in CRC.

Key Results

  • 38 Plausible AI Target Genes Identified: The high-resolution AI landscape analysis pinpointed 38 genes as likely targets of chromosomal gains or losses.
  • 79 Genes Regulating Cell Growth Identified: CRISPR-Cas9 screens identified 79 genes within AI peaks that are crucial for cell growth.
  • TP53 Loss Linked to Widespread AI: TP53 loss was found in 63% of the analyzed CRCs and was implicated as a sufficient driver of AI.
  • AI Influences Somatic Mutation Rate: WGS data revealed that copy number aberrations can influence the rate of detected somatic point mutations.
  • Favorable Prognosis Genes are Lost, Unfavorable Genes are Gained: Genes associated with favorable patient prognosis were more frequently lost, while those linked to unfavorable prognosis were more often gained.
  • MYC is Essential for CRC Cell Growth: MYC was identified as a shared hit in both knockout and activation screens, highlighting its central role in CRC cell proliferation.

Limitations and Future Work

  • Resolution of Rare Events: While the study achieved high resolution, the authors acknowledge that improved resolution of relatively rare AI events can be anticipated with larger datasets.
  • Context-Specific Regulatory States: The study notes that different cell lines displayed distinct regulatory states within the identified transcription factor network, suggesting that individual tumors may utilize different upstream mechanisms to drive MYC expression.
  • Therapeutic Implications: The authors suggest that understanding the main AI targets and their contexts in tumorigenesis is essential for designing functional experiments and modeling responses to therapy. Further study is warranted to explore the differential requirement of AI target genes for cell growth and how different AI events and mutations might influence treatment response.
  • Broader Application: The authors propose that a crucial next step is to robustly identify the main targets of gene dosage aberrations across all tumor types, aiming for a comprehensive catalog of genes involved in cancer.

Summary updated

Abstract

Point mutations in cancer have been extensively studied but chromosomal gains and losses have been more challenging to interpret due to their unspecific nature. Here we examine high-resolution allelic imbalance (AI) landscape in 1699 colorectal cancers, 256 of which have been whole-genome sequenced (WGSed). The imbalances pinpoint 38 genes as plausible AI targets based on previous knowledge. Unbiased CRISPR-Cas9 knockout and activation screens identified in total 79 genes within AI peaks regulating cell growth. Genetic and functional data implicate loss of TP53 as a sufficient driver of AI. The WGS highlights an influence of copy number aberrations on the rate of detected somatic point mutations. Importantly, the data reveal several associations between AI target genes, suggesting a role for a network of lineage-determining transcription factors in colorectal tumorigenesis. Overall, the results unravel the contribution of AI in colorectal cancer and provide a plausible explanation why so few genes are commonly affected by point mutations in cancers.
BibTeX
@inproceedings{palin2018contribution,
  author = {Kimmo Palin and Esa Pitkänen and Mikko Turunen and Biswajyoti Sahu and Päivi Pihlajamaa and Teemu Kivioja and Eevi Kaasinen and Niko Välimäki and Ulrika A. Hänninen and Tatiana Cajuso and Mervi Aavikko and Sari Tuupanen and Outi Kilpivaara and Linda van den Berg and Johanna Kondelin and Tomas Tanskanen and Riku Katainen and Marta Grau and Heli Rauanheimo and Roosa‐Maria Plaketti and Aurora Taira and Päivi Sulo and Tuomo Hartonen and Kashyap Dave and Bernhard Schmierer and Sandeep K. Botla and Maria Sokolova and Anna Vähärautio and Kornelia Gladysz and Halit Ongen and Emmanouil T. Dermitzakis and Jesper B. Bramsen and Torben F. Ørntoft and Claus L. Andersen and Ari Ristimäki and Anna Lepistö and Laura Renkonen‐Sinisalo and Jukka‐Pekka Mecklin and Jussi Taipale and Lauri A. Aaltonen},
  title = {{Contribution of allelic imbalance to colorectal cancer}},
  booktitle = {Nature Communications},
  year = {2018},
  doi = {10.1038/s41467-018-06132-1},
}

Loading related content...

Figure